Guard Therapeutics International AB (publ)

Stockholm Stock Exchange GUARD.ST

Guard Therapeutics International AB (publ) EBITDA Margin for the year ending December 31, 2023

Guard Therapeutics International AB (publ) EBITDA Margin is NA for the year ending December 31, 2023. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Stockholm Stock Exchange: GUARD.ST

Guard Therapeutics International AB (publ)

CEO	Mr. Tobias Larsson Agervald
IPO Date	April 3, 2013
Location	Sweden
Headquarters	Nybrogatan 34, 2 tr
Employees	11
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019. Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.

Key trends

Past 5 years